Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

News on Inhibikase's promising treatments for PAH and Parkinson's Disease, supported by FDA approval and substantial funding.

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study from Karolinska ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

Hypochondria can, in extreme cases, leave people unable to hold down a job or make it impossible for them to leave the house, ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...